Preoperative treatment of HER2-positive breast cancer

被引：0
作者：
Wysocki, Piotr J. [1 ]
Krzakowski, Maciej [2 ]
机构：
[1] Jagiellonian Univ Coll Med, Dept Oncol, Krakow, Poland
[2] Maria Sklodowska Curie Natl Res Inst Oncol, Dept Lung Canc & Chest Tumours, Warsaw, Poland
来源：
ONCOLOGY IN CLINICAL PRACTICE | 2020年 / 16卷 / 02期
关键词：
neoadjuvant treatment; preoperative chemotherapy; HER2-positive; pertuzumab; trastuzumab; breast cancer; PACLITAXEL PLUS TRASTUZUMAB; PHASE-III TRIAL; ADJUVANT CHEMOTHERAPY; OPEN-LABEL; NEOADJUVANT; LAPATINIB; MULTICENTER; PERTUZUMAB; THERAPY; COMBINATION;
D O I：
10.5603/OCP.2020.0002
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Preoperative chemotherapy is more and more frequently used in the treatment of localized and locally-advanced breast cancer. This approach not only creates optimal conditions for organ-sparing surgery but also provides us with valuable information on the biology and chemosensitivity of cancer. This data is then crucial for the choice of systemic adjuvant therapy. The availability of two anti-HER2 targeted agents (pertuzumab and trastuzumab) for the neoadjuvant treatment of breast cancer significantly improves the efficacy of this approach. Significantly increased percentage of patients experiencing complete pathological response correlates with improved outcomes. This article is aimed at summarizing current knowledge regarding the role of pertuzumab in neoadjuvant treatment of HER2-positive breast cancer and comprises essential guidelines for the optimal use of currently reimbursed therapies in this disease.
引用
收藏
页码：69 / 74
页数：6
相关论文
共 26 条
  • [1] Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM/2006-14 trial
    Alba, E.
    Albanell, J.
    de la Haba, J.
    Barnadas, A.
    Calvo, L.
    Sanchez-Rovira, P.
    Ramos, M.
    Rojo, F.
    Burgues, O.
    Carrasco, E.
    Caballero, R.
    Porras, I.
    Tibau, A.
    Camara, M. C.
    Lluch, A.
    [J]. BRITISH JOURNAL OF CANCER, 2014, 110 (05) : 1139 - 1147
  • [2] Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials
    Alberro, J. A.
    Ballester, B.
    Deulofeu, P.
    Fabregas, R.
    Fraile, M.
    Gubern, J. M.
    Janer, J.
    Moral, A.
    de Pablo, J. L.
    Penalva, G.
    Puig, P.
    Ramos, M.
    Rojo, R.
    Santesteban, P.
    Serra, C.
    Sola, M.
    Solarnau, L.
    Solsona, J.
    Veloso, E.
    Vidal, S.
    Abe, O.
    Abe, R.
    Enomoto, K.
    Kikuchi, K.
    Koyama, H.
    Masuda, H.
    Nomura, Y.
    Ohashi, Y.
    Sakai, K.
    Sugimachi, K.
    Toi, M.
    Tominaga, T.
    Uchino, J.
    Yoshida, M.
    Coles, C. E.
    Haybittle, J. L.
    Moebus, V.
    Leonard, C. F.
    Calais, G.
    Garaud, P.
    Collett, V.
    Davies, C.
    Delmestri, A.
    Sayer, J.
    Harvey, V. J.
    Holdaway, I. M.
    Kay, R. G.
    Mason, B. H.
    Forbe, J. F.
    Franci, P. A.
    [J]. LANCET ONCOLOGY, 2018, 19 (01) : 27 - 39
  • [3] Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
    Baselga, Jose
    Bradbury, Ian
    Eidtmann, Holger
    Di Cosimo, Serena
    de Azambuja, Evandro
    Aura, Claudia
    Gomez, Henry
    Dinh, Phuong
    Fauria, Karine
    Van Dooren, Veerle
    Aktan, Gursel
    Goldhirsch, Aron
    Chang, Tsai-Wang
    Horvath, Zsolt
    Coccia-Portugal, Maria
    Domont, Julien
    Tseng, Ling-Min
    Kunz, Georg
    Sohn, Joo Hyuk
    Semiglazov, Vladimir
    Lerzo, Guillermo
    Palacova, Marketa
    Probachai, Volodymyr
    Pusztai, Lajos
    Untch, Michael
    Gelber, Richard D.
    Piccart-Gebhart, Martine
    [J]. LANCET, 2012, 379 (9816) : 633 - 640
  • [4] Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial
    Buzdar, Aman U.
    Suman, Vera J.
    Meric-Bernstam, Funda
    Leitch, A. Marilyn
    Ellis, Matthew J.
    Boughey, Judy C.
    Unzeitig, Gary
    Royce, Melanie
    McCall, Linda M.
    Ewer, Michael S.
    Hunt, Kelly K.
    [J]. LANCET ONCOLOGY, 2013, 14 (13) : 1317 - 1325
  • [5] Buzdar AU, 2002, CLIN CANCER RES, V8, P1073
  • [6] Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib
    Carey, Lisa A.
    Berry, Donald A.
    Cirrincione, Constance T.
    Barry, William T.
    Pitcher, Brandelyn N.
    Harris, Lyndsay N.
    Ollila, David W.
    Krop, Ian E.
    Henry, Norah Lynn
    Weckstein, Douglas J.
    Anders, Carey K.
    Singh, Baljit
    Hoadley, Katherine A.
    Iglesia, Michael
    Cheang, Maggie Chon U.
    Perou, Charles M.
    Winer, Eric P.
    Hudis, Clifford A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (06) : 542 - +
  • [7] Cortazar P, 2019, LANCET, V393, P986
  • [8] Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
    Gianni, Luca
    Pienkowski, Tadeusz
    Im, Young-Hyuck
    Roman, Laslo
    Tseng, Ling-Ming
    Liu, Mei-Ching
    Lluch, Ana
    Staroslawska, Elzbieta
    de la Haba-Rodriguez, Juan
    Im, Seock-Ah
    Pedrini, Jose Luiz
    Poirier, Brigitte
    Morandi, Paolo
    Semiglazov, Vladimir
    Srimuninnimit, Vichien
    Bianchi, Giulia
    Szado, Tania
    Ratnayake, Jayantha
    Ross, Graham
    Valagussa, Pinuccia
    [J]. LANCET ONCOLOGY, 2012, 13 (01) : 25 - 32
  • [9] Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort
    Gianni, Luca
    Eiermann, Wolfgang
    Semiglazov, Vladimir
    Manikhas, Alexey
    Lluch, Ana
    Tjulandin, Sergey
    Zambetti, Milvia
    Vazquez, Federico
    Byakhow, Mikhail
    Lichinitser, Mikhail
    Angel Climent, Miguel
    Ciruelos, Eva
    Ojeda, Belen
    Mansutti, Mauro
    Bozhok, Alla
    Baronio, Roberta
    Feyereislova, Andrea
    Barton, Claire
    Valagussa, Pinuccia
    Baselga, Jose
    [J]. LANCET, 2010, 375 (9712) : 377 - 384
  • [10] Preoperative Chemotherapy Plus Trastuzumab, Lapatinib, or Both in Human Epidermal Growth Factor Receptor 2-Positive Operable Breast Cancer: Results of the Randomized Phase II CHER-LOB Study
    Guarneri, Valentina
    Frassoldati, Antonio
    Bottini, Alberto
    Cagossi, Katia
    Bisagni, Giancarlo
    Sarti, Samanta
    Ravaioli, Alberto
    Cavanna, Luigi
    Giardina, Giovanni
    Musolino, Antonino
    Untch, Michael
    Orlando, Laura
    Artioli, Fabrizio
    Boni, Corrado
    Generali, Daniele Giulio
    Serra, Patrizia
    Bagnalasta, Michela
    Marini, Luca
    Piacentini, Federico
    D'Amico, Roberto
    Conte, PierFranco
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (16) : 1989 - 1995
123